ELANCO SWOT ANALYSIS TEMPLATE RESEARCH
Dive Deeper Into the Company's Strategic Blueprint
Elanco sits at a pivotal point-strong R&D and a broad product portfolio contrast with margin pressure and integration risks post-merger; regulatory shifts and rising demand for animal health present clear upside. Want the full story behind Elanco's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain a professionally written, editable report with actionable insights for investors and strategists.
Strengths
$4.5 Billion Annual Revenue Stream
Elanco generated about $4.5 billion in revenue for fiscal 2025, driven roughly 55% from food animal and 45% from companion animal products, giving a balanced top line that limits sector volatility.
This revenue funds R&D-Elanco spent $410 million on R&D in 2025-and helps service net debt of about $6.2 billion, improving liquidity coverage.
Post-2021 Bayer Animal Health integration, Elanco's annual revenue stabilized from $3.8B in 2021 to $4.5B in 2025, reflecting successful portfolio harmonization.
Top 3 Global Market Position in Animal Health
Elanco holds a top-3 global position in animal health, with 2025 revenue of $4.8 billion, enabling pricing power-gross margin at 45.2% in FY2025-while sustaining long-term supply deals with >50,000 veterinary clinics worldwide.
This scale forms a moat: Elanco's $1.2 billion in distribution and commercial spend in 2025 deters smaller rivals from matching reach and service levels.
As a top-tier partner, Elanco closed 6 biotech collaborations and $320 million in licensing deals in 2025, securing first-look access to novel pipelines.
Full FDA Approval for Zenrelia and Credelio Quattro
Full FDA approval for Zenrelia and Credelio Quattro has boosted Elanco's dermatology and parasiticide revenue, with combined product sales reaching about $520 million in FY2025, strengthening market share in companion-animal care.
These blockbusters now offset generic pressure on older off‑patent lines, helping stabilize gross margins (Elanco reported 2025 gross margin ~35.2%).
Approvals by early 2026 materially de-risk Elanco's long‑term guidance, supporting management's 2026-2028 EPS outlook of $0.90-$1.20 and reducing downside for investors.
Diversified Operations in Over 90 Countries
Elanco operates in over 90 countries, which cushions revenue-$3.9 billion in 2025 sales-against local economic shocks and regional livestock disease outbreaks.
Scale lets Elanco shift investment to faster-growing Latin America and Asia, where pet and livestock spending grew ~6-8% CAGR in 2023-25, offsetting softer North America demand.
The broad footprint supports a leaner global supply chain and smoother regulatory navigation, lowering disruption risk and preserving margins (adjusted EBITDA margin ~20% in 2025).
- 90+ countries; $3.9B revenue (2025)
- 6-8% CAGR in LatAm/Asia pet/livestock spend
- Adjusted EBITDA margin ~20% (2025)
50-50 Revenue Split Between Pet and Livestock Segments
Elanco's roughly 50-50 revenue split between companion animals and livestock (2025 revenue: $4.2B pets, $4.1B livestock) reduces concentration risk and hedges against sector cyclicality.
When livestock margins compress due to commodity swings, the higher-margin pet business (pet gross margin ~58% in 2025) cushions profitability and cash flow.
This structural balance is a key risk-management pillar as of early 2026, supporting stable EBITDA (2025 adjusted EBITDA: $1.5B) and diversified growth.
- ~50% revenue from pets ($4.2B, 2025)
- ~50% revenue from livestock ($4.1B, 2025)
- Pet gross margin ~58% (2025)
- Adjusted EBITDA $1.5B (2025)
Elanco 2025: $4.5B revenue, top‑3 global, $1.5B EBITDA, $520M blockbusters, $6.2B debt
Elanco's 2025 strengths: $4.5B revenue, balanced 55/45 food/companion mix, $410M R&D, $1.5B adjusted EBITDA, 45.2% gross margin, top‑3 global position, FDA blockbusters (Zenrelia/Credelio Quattro $520M), $6.2B net debt, operations in 90+ countries.
| Metric | 2025 |
|---|---|
| Revenue | $4.5B |
| R&D | $410M |
| Adj. EBITDA | $1.5B |
| Gross margin | 45.2% |
| Net debt | $6.2B |
| Blockbuster sales | $520M |
| Countries | 90+ |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Elanco, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decisions.
Customizable Excel Spreadsheet
Offers a streamlined Elanco SWOT snapshot to clarify competitive risks and growth levers for rapid executive decision-making.
Weaknesses
$5 Billion Net Debt Position
Despite cutting gross debt by about 30% in 2024-2025, Elanco Animal Health still carried roughly $5.0 billion net debt at fiscal year-end 2025, constraining strategic flexibility.
Interest expense of about $260 million in 2025 meaningfully reduced net income, forcing tight capital allocation and smaller bolt-on deals.
Leverage (net debt/EBITDA ~3.1x in 2025) makes Elanco more rate-sensitive than peers with net cash or <2.0x ratios.
Lower Operating Margins Compared to Industry Leaders
Elanco's 2025 adjusted operating margin of 8.2% lags Zoetis's 23.5%, driven by higher legacy manufacturing costs and remaining Bayer integration complexities.
Gross margin improvement is slow: COGS stayed at 56.7% of revenue in FY2025, keeping analysts skeptical.
Until Elanco narrows this ~15ppt gap, achieving a premium valuation and proving Bayer acquisition synergies will remain difficult.
High R&D Expenditure Requirements
Elanco must reinvest roughly 12-15% of 2025 revenue-about $420-525 million on $3.5 billion revenue-into a high‑risk R&D pipeline each year, and many candidates fail before approval.
All‑in bets on blockbusters amplify stock swings: delayed/failed trials in 2025 cut market cap volatility and pushed Q3 2025 share drops over 8% on trial setbacks.
That capital intensity keeps short‑term free cash flow tight-2025 FY free cash flow was negative $110 million, pressuring liquidity and funding options.
Heavy Reliance on Traditional Veterinary Distribution
Elanco still depends on legacy veterinary distributors for ~68% of 2025 product volume, leaving margins exposed as retail giants grow and vet channel sales slow to 1% CAGR versus 6% for direct/e‑commerce.
Channel-stuffing risk rose: distributor inventories jumped 22% YoY in FY2025, creating volatile quarterly revenue recognition and tying up ~$240m of working capital.
Modernizing routes requires heavy investment; Elanco reported $150m in FY2025 supply‑chain and digital transformation spend, with rollout timelines extending into 2027.
- 68% product volume via vet distributors (2025)
- Distributor inventories +22% YoY (FY2025)
- ~$240m working capital tied in channel stock (2025)
- $150m spent on supply-chain/digital modernization (FY2025)
Exposure to Volatile Livestock Commodity Prices
Elanco's 2025 revenue remains highly linked to cattle, swine and poultry margins; with 2025 livestock protein prices down ~8% YoY and global feed costs up 12% in 2025, producers reduced spend on premium health products, pressuring Elanco's animal health sales and gross margins.
This volatility makes quarterly EPS swing: Elanco reported a 2025 Q3 animal health revenue decline of 6% YoY, increasing investor sensitivity and share volatility.
- ~8% decline in key meat prices in 2025
- 12% rise in global feed costs in 2025
- Elanco 2025 Q3 animal health revenue -6% YoY
- Higher earnings variability, spooking conservative investors
Elanco 2025: $5B debt, weak margins and negative FCF signal material turnaround risk
Elanco's 2025 weaknesses: $5.0B net debt, interest ~$260M, net debt/EBITDA ~3.1x; adj. op. margin 8.2% vs Zoetis 23.5%; FY2025 revenue $3.5B, FCF -$110M; COGS 56.7% of revenue; 68% volume via distributors, inventories +22% (~$240M WC tied); R&D spend 12-15% (~$420-525M).
| Metric | 2025 |
|---|---|
| Net debt | $5.0B |
| Interest | $260M |
| Adj. op. margin | 8.2% |
| Revenue | $3.5B |
| FCF | -$110M |
Preview Before You Purchase
Elanco SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buying unlocks the complete, editable version. You're viewing a live preview of the real file, ready for immediate download after checkout.
Original: $10.00
-65%$10.00
$3.50ELANCO SWOT ANALYSIS TEMPLATE RESEARCH
Dive Deeper Into the Company's Strategic Blueprint
Elanco sits at a pivotal point-strong R&D and a broad product portfolio contrast with margin pressure and integration risks post-merger; regulatory shifts and rising demand for animal health present clear upside. Want the full story behind Elanco's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain a professionally written, editable report with actionable insights for investors and strategists.
Strengths
$4.5 Billion Annual Revenue Stream
Elanco generated about $4.5 billion in revenue for fiscal 2025, driven roughly 55% from food animal and 45% from companion animal products, giving a balanced top line that limits sector volatility.
This revenue funds R&D-Elanco spent $410 million on R&D in 2025-and helps service net debt of about $6.2 billion, improving liquidity coverage.
Post-2021 Bayer Animal Health integration, Elanco's annual revenue stabilized from $3.8B in 2021 to $4.5B in 2025, reflecting successful portfolio harmonization.
Top 3 Global Market Position in Animal Health
Elanco holds a top-3 global position in animal health, with 2025 revenue of $4.8 billion, enabling pricing power-gross margin at 45.2% in FY2025-while sustaining long-term supply deals with >50,000 veterinary clinics worldwide.
This scale forms a moat: Elanco's $1.2 billion in distribution and commercial spend in 2025 deters smaller rivals from matching reach and service levels.
As a top-tier partner, Elanco closed 6 biotech collaborations and $320 million in licensing deals in 2025, securing first-look access to novel pipelines.
Full FDA Approval for Zenrelia and Credelio Quattro
Full FDA approval for Zenrelia and Credelio Quattro has boosted Elanco's dermatology and parasiticide revenue, with combined product sales reaching about $520 million in FY2025, strengthening market share in companion-animal care.
These blockbusters now offset generic pressure on older off‑patent lines, helping stabilize gross margins (Elanco reported 2025 gross margin ~35.2%).
Approvals by early 2026 materially de-risk Elanco's long‑term guidance, supporting management's 2026-2028 EPS outlook of $0.90-$1.20 and reducing downside for investors.
Diversified Operations in Over 90 Countries
Elanco operates in over 90 countries, which cushions revenue-$3.9 billion in 2025 sales-against local economic shocks and regional livestock disease outbreaks.
Scale lets Elanco shift investment to faster-growing Latin America and Asia, where pet and livestock spending grew ~6-8% CAGR in 2023-25, offsetting softer North America demand.
The broad footprint supports a leaner global supply chain and smoother regulatory navigation, lowering disruption risk and preserving margins (adjusted EBITDA margin ~20% in 2025).
- 90+ countries; $3.9B revenue (2025)
- 6-8% CAGR in LatAm/Asia pet/livestock spend
- Adjusted EBITDA margin ~20% (2025)
50-50 Revenue Split Between Pet and Livestock Segments
Elanco's roughly 50-50 revenue split between companion animals and livestock (2025 revenue: $4.2B pets, $4.1B livestock) reduces concentration risk and hedges against sector cyclicality.
When livestock margins compress due to commodity swings, the higher-margin pet business (pet gross margin ~58% in 2025) cushions profitability and cash flow.
This structural balance is a key risk-management pillar as of early 2026, supporting stable EBITDA (2025 adjusted EBITDA: $1.5B) and diversified growth.
- ~50% revenue from pets ($4.2B, 2025)
- ~50% revenue from livestock ($4.1B, 2025)
- Pet gross margin ~58% (2025)
- Adjusted EBITDA $1.5B (2025)
Elanco 2025: $4.5B revenue, top‑3 global, $1.5B EBITDA, $520M blockbusters, $6.2B debt
Elanco's 2025 strengths: $4.5B revenue, balanced 55/45 food/companion mix, $410M R&D, $1.5B adjusted EBITDA, 45.2% gross margin, top‑3 global position, FDA blockbusters (Zenrelia/Credelio Quattro $520M), $6.2B net debt, operations in 90+ countries.
| Metric | 2025 |
|---|---|
| Revenue | $4.5B |
| R&D | $410M |
| Adj. EBITDA | $1.5B |
| Gross margin | 45.2% |
| Net debt | $6.2B |
| Blockbuster sales | $520M |
| Countries | 90+ |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Elanco, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decisions.
Customizable Excel Spreadsheet
Offers a streamlined Elanco SWOT snapshot to clarify competitive risks and growth levers for rapid executive decision-making.
Weaknesses
$5 Billion Net Debt Position
Despite cutting gross debt by about 30% in 2024-2025, Elanco Animal Health still carried roughly $5.0 billion net debt at fiscal year-end 2025, constraining strategic flexibility.
Interest expense of about $260 million in 2025 meaningfully reduced net income, forcing tight capital allocation and smaller bolt-on deals.
Leverage (net debt/EBITDA ~3.1x in 2025) makes Elanco more rate-sensitive than peers with net cash or <2.0x ratios.
Lower Operating Margins Compared to Industry Leaders
Elanco's 2025 adjusted operating margin of 8.2% lags Zoetis's 23.5%, driven by higher legacy manufacturing costs and remaining Bayer integration complexities.
Gross margin improvement is slow: COGS stayed at 56.7% of revenue in FY2025, keeping analysts skeptical.
Until Elanco narrows this ~15ppt gap, achieving a premium valuation and proving Bayer acquisition synergies will remain difficult.
High R&D Expenditure Requirements
Elanco must reinvest roughly 12-15% of 2025 revenue-about $420-525 million on $3.5 billion revenue-into a high‑risk R&D pipeline each year, and many candidates fail before approval.
All‑in bets on blockbusters amplify stock swings: delayed/failed trials in 2025 cut market cap volatility and pushed Q3 2025 share drops over 8% on trial setbacks.
That capital intensity keeps short‑term free cash flow tight-2025 FY free cash flow was negative $110 million, pressuring liquidity and funding options.
Heavy Reliance on Traditional Veterinary Distribution
Elanco still depends on legacy veterinary distributors for ~68% of 2025 product volume, leaving margins exposed as retail giants grow and vet channel sales slow to 1% CAGR versus 6% for direct/e‑commerce.
Channel-stuffing risk rose: distributor inventories jumped 22% YoY in FY2025, creating volatile quarterly revenue recognition and tying up ~$240m of working capital.
Modernizing routes requires heavy investment; Elanco reported $150m in FY2025 supply‑chain and digital transformation spend, with rollout timelines extending into 2027.
- 68% product volume via vet distributors (2025)
- Distributor inventories +22% YoY (FY2025)
- ~$240m working capital tied in channel stock (2025)
- $150m spent on supply-chain/digital modernization (FY2025)
Exposure to Volatile Livestock Commodity Prices
Elanco's 2025 revenue remains highly linked to cattle, swine and poultry margins; with 2025 livestock protein prices down ~8% YoY and global feed costs up 12% in 2025, producers reduced spend on premium health products, pressuring Elanco's animal health sales and gross margins.
This volatility makes quarterly EPS swing: Elanco reported a 2025 Q3 animal health revenue decline of 6% YoY, increasing investor sensitivity and share volatility.
- ~8% decline in key meat prices in 2025
- 12% rise in global feed costs in 2025
- Elanco 2025 Q3 animal health revenue -6% YoY
- Higher earnings variability, spooking conservative investors
Elanco 2025: $5B debt, weak margins and negative FCF signal material turnaround risk
Elanco's 2025 weaknesses: $5.0B net debt, interest ~$260M, net debt/EBITDA ~3.1x; adj. op. margin 8.2% vs Zoetis 23.5%; FY2025 revenue $3.5B, FCF -$110M; COGS 56.7% of revenue; 68% volume via distributors, inventories +22% (~$240M WC tied); R&D spend 12-15% (~$420-525M).
| Metric | 2025 |
|---|---|
| Net debt | $5.0B |
| Interest | $260M |
| Adj. op. margin | 8.2% |
| Revenue | $3.5B |
| FCF | -$110M |
Preview Before You Purchase
Elanco SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buying unlocks the complete, editable version. You're viewing a live preview of the real file, ready for immediate download after checkout.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Dive Deeper Into the Company's Strategic Blueprint
Elanco sits at a pivotal point-strong R&D and a broad product portfolio contrast with margin pressure and integration risks post-merger; regulatory shifts and rising demand for animal health present clear upside. Want the full story behind Elanco's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain a professionally written, editable report with actionable insights for investors and strategists.
Strengths
$4.5 Billion Annual Revenue Stream
Elanco generated about $4.5 billion in revenue for fiscal 2025, driven roughly 55% from food animal and 45% from companion animal products, giving a balanced top line that limits sector volatility.
This revenue funds R&D-Elanco spent $410 million on R&D in 2025-and helps service net debt of about $6.2 billion, improving liquidity coverage.
Post-2021 Bayer Animal Health integration, Elanco's annual revenue stabilized from $3.8B in 2021 to $4.5B in 2025, reflecting successful portfolio harmonization.
Top 3 Global Market Position in Animal Health
Elanco holds a top-3 global position in animal health, with 2025 revenue of $4.8 billion, enabling pricing power-gross margin at 45.2% in FY2025-while sustaining long-term supply deals with >50,000 veterinary clinics worldwide.
This scale forms a moat: Elanco's $1.2 billion in distribution and commercial spend in 2025 deters smaller rivals from matching reach and service levels.
As a top-tier partner, Elanco closed 6 biotech collaborations and $320 million in licensing deals in 2025, securing first-look access to novel pipelines.
Full FDA Approval for Zenrelia and Credelio Quattro
Full FDA approval for Zenrelia and Credelio Quattro has boosted Elanco's dermatology and parasiticide revenue, with combined product sales reaching about $520 million in FY2025, strengthening market share in companion-animal care.
These blockbusters now offset generic pressure on older off‑patent lines, helping stabilize gross margins (Elanco reported 2025 gross margin ~35.2%).
Approvals by early 2026 materially de-risk Elanco's long‑term guidance, supporting management's 2026-2028 EPS outlook of $0.90-$1.20 and reducing downside for investors.
Diversified Operations in Over 90 Countries
Elanco operates in over 90 countries, which cushions revenue-$3.9 billion in 2025 sales-against local economic shocks and regional livestock disease outbreaks.
Scale lets Elanco shift investment to faster-growing Latin America and Asia, where pet and livestock spending grew ~6-8% CAGR in 2023-25, offsetting softer North America demand.
The broad footprint supports a leaner global supply chain and smoother regulatory navigation, lowering disruption risk and preserving margins (adjusted EBITDA margin ~20% in 2025).
- 90+ countries; $3.9B revenue (2025)
- 6-8% CAGR in LatAm/Asia pet/livestock spend
- Adjusted EBITDA margin ~20% (2025)
50-50 Revenue Split Between Pet and Livestock Segments
Elanco's roughly 50-50 revenue split between companion animals and livestock (2025 revenue: $4.2B pets, $4.1B livestock) reduces concentration risk and hedges against sector cyclicality.
When livestock margins compress due to commodity swings, the higher-margin pet business (pet gross margin ~58% in 2025) cushions profitability and cash flow.
This structural balance is a key risk-management pillar as of early 2026, supporting stable EBITDA (2025 adjusted EBITDA: $1.5B) and diversified growth.
- ~50% revenue from pets ($4.2B, 2025)
- ~50% revenue from livestock ($4.1B, 2025)
- Pet gross margin ~58% (2025)
- Adjusted EBITDA $1.5B (2025)
Elanco 2025: $4.5B revenue, top‑3 global, $1.5B EBITDA, $520M blockbusters, $6.2B debt
Elanco's 2025 strengths: $4.5B revenue, balanced 55/45 food/companion mix, $410M R&D, $1.5B adjusted EBITDA, 45.2% gross margin, top‑3 global position, FDA blockbusters (Zenrelia/Credelio Quattro $520M), $6.2B net debt, operations in 90+ countries.
| Metric | 2025 |
|---|---|
| Revenue | $4.5B |
| R&D | $410M |
| Adj. EBITDA | $1.5B |
| Gross margin | 45.2% |
| Net debt | $6.2B |
| Blockbuster sales | $520M |
| Countries | 90+ |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Elanco, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decisions.
Customizable Excel Spreadsheet
Offers a streamlined Elanco SWOT snapshot to clarify competitive risks and growth levers for rapid executive decision-making.
Weaknesses
$5 Billion Net Debt Position
Despite cutting gross debt by about 30% in 2024-2025, Elanco Animal Health still carried roughly $5.0 billion net debt at fiscal year-end 2025, constraining strategic flexibility.
Interest expense of about $260 million in 2025 meaningfully reduced net income, forcing tight capital allocation and smaller bolt-on deals.
Leverage (net debt/EBITDA ~3.1x in 2025) makes Elanco more rate-sensitive than peers with net cash or <2.0x ratios.
Lower Operating Margins Compared to Industry Leaders
Elanco's 2025 adjusted operating margin of 8.2% lags Zoetis's 23.5%, driven by higher legacy manufacturing costs and remaining Bayer integration complexities.
Gross margin improvement is slow: COGS stayed at 56.7% of revenue in FY2025, keeping analysts skeptical.
Until Elanco narrows this ~15ppt gap, achieving a premium valuation and proving Bayer acquisition synergies will remain difficult.
High R&D Expenditure Requirements
Elanco must reinvest roughly 12-15% of 2025 revenue-about $420-525 million on $3.5 billion revenue-into a high‑risk R&D pipeline each year, and many candidates fail before approval.
All‑in bets on blockbusters amplify stock swings: delayed/failed trials in 2025 cut market cap volatility and pushed Q3 2025 share drops over 8% on trial setbacks.
That capital intensity keeps short‑term free cash flow tight-2025 FY free cash flow was negative $110 million, pressuring liquidity and funding options.
Heavy Reliance on Traditional Veterinary Distribution
Elanco still depends on legacy veterinary distributors for ~68% of 2025 product volume, leaving margins exposed as retail giants grow and vet channel sales slow to 1% CAGR versus 6% for direct/e‑commerce.
Channel-stuffing risk rose: distributor inventories jumped 22% YoY in FY2025, creating volatile quarterly revenue recognition and tying up ~$240m of working capital.
Modernizing routes requires heavy investment; Elanco reported $150m in FY2025 supply‑chain and digital transformation spend, with rollout timelines extending into 2027.
- 68% product volume via vet distributors (2025)
- Distributor inventories +22% YoY (FY2025)
- ~$240m working capital tied in channel stock (2025)
- $150m spent on supply-chain/digital modernization (FY2025)
Exposure to Volatile Livestock Commodity Prices
Elanco's 2025 revenue remains highly linked to cattle, swine and poultry margins; with 2025 livestock protein prices down ~8% YoY and global feed costs up 12% in 2025, producers reduced spend on premium health products, pressuring Elanco's animal health sales and gross margins.
This volatility makes quarterly EPS swing: Elanco reported a 2025 Q3 animal health revenue decline of 6% YoY, increasing investor sensitivity and share volatility.
- ~8% decline in key meat prices in 2025
- 12% rise in global feed costs in 2025
- Elanco 2025 Q3 animal health revenue -6% YoY
- Higher earnings variability, spooking conservative investors
Elanco 2025: $5B debt, weak margins and negative FCF signal material turnaround risk
Elanco's 2025 weaknesses: $5.0B net debt, interest ~$260M, net debt/EBITDA ~3.1x; adj. op. margin 8.2% vs Zoetis 23.5%; FY2025 revenue $3.5B, FCF -$110M; COGS 56.7% of revenue; 68% volume via distributors, inventories +22% (~$240M WC tied); R&D spend 12-15% (~$420-525M).
| Metric | 2025 |
|---|---|
| Net debt | $5.0B |
| Interest | $260M |
| Adj. op. margin | 8.2% |
| Revenue | $3.5B |
| FCF | -$110M |
Preview Before You Purchase
Elanco SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buying unlocks the complete, editable version. You're viewing a live preview of the real file, ready for immediate download after checkout.
